Table 2 Treatment and outcome of synchronous/ metachronous malignant histiocytosis associated with primary hemopathy
From: Synchronous clonally related anaplastic large cell lymphoma and malignant histiocytosis
Refe-rence | Case/ review | Lymphoma | Clonal relationship with MH (Table 1) | Interval between initial hemopathie and MH | Successive treatments from the MH diagnosis | Outcome from MH diagnosis |
|---|---|---|---|---|---|---|
2 | Case | FL | Yes | Synchronous | CIT (1st line) CT (2nd line) | Died 11 months later |
Review | Transformed FL (DLBCL) | Yes | 13 years after initial FL diagnosis | CIT (1st line) CT (2nd line) | Died in the year | |
Review | DLBCL | No | 1 year | CIT (1st line) CT + RT (2nd line) Supportive care | Died quickly (delay?) | |
Review | FL | No | 8 years | Supportive care | Died 3 months later | |
Review | FL | Yes | 4 years | Protease inhibitor | Died 9 months later | |
Review | MCL | Yes | 18 months | CIT Surgery | Progression | |
Review | MZL | Yes | 6 years | No treatment | Died 2 months later | |
7 | Case | BL | Yes | 22 months | High intensity chemo-immunotherapy | Alive 9 years after treatment |
8 | Case | B-ALL | Yes | 1 year | High intensity chemotherapy (1st and 2nd line) BRAFi + lenalidomide (3rd line) | Secondary MDS – died 3 years later |
9 | Case | FL | Yes | Few months | Radiation (1st line), Chemo-immunotherapy (2nd and 3rd line), chemotherapy + ibrutinib (4th line) | Died in the year |
10 | Case | SMZL | No | ND | No treatment | Died before introduction of treatment |
12 | Case | AITL | No | Synchronous | No treatment (declined) | Died 5 months later |